Search
Pitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigationalPitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessiv...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersCurcumin
go.drugbank.com/drugs/DB11672ApprovedInvestigationalCurcumin, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglyce...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesFruquintinib
go.drugbank.com/drugs/DB11679ApprovedInvestigationalFruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 SubstratesAcalabrutinib
go.drugbank.com/drugs/DB11703ApprovedInvestigationalTo date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administer...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsEncorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as BRAFTOVI, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesIcotinib
go.drugbank.com/drugs/DB11737InvestigationalIcotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersVonoprazan
go.drugbank.com/drugs/DB11739ApprovedInvestigationalVonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders. Unlike proton-pu...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesEbastine
go.drugbank.com/drugs/DB11742ApprovedInvestigationalWithdrawnEbastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalRenal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesNeratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib i...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors